Drug Profile


Alternative Names: SENS-111

Latest Information Update: 24 Aug 2015

Price : $50

At a glance

  • Originator Palau Pharma
  • Developer Palau Pharma; Sensorion
  • Class Small molecules
  • Mechanism of Action Histamine H4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Vertigo
  • Preclinical Tinnitus

Most Recent Events

  • 21 Jan 2015 Preclinical trials in Vertigo in France (unspecified route)
  • 21 Jan 2015 Preclinical trials in Tinnitus in France (unspecified route)
  • 01 Jan 2015 Phase-Ib clinical trials in Vertigo in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top